SS Innovations International (SSII) 10-K 6 Sep 22 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Sep. 02, 2022	Jun. 30, 2020
Document Information Line Items
Entity Registrant Name	AVRA MEDICAL ROBOTICS, INC
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		39,197,099
Entity Public Float			$ 0
Amendment Flag	false
Entity Central Index Key	0001676163
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity File Number	333-216054
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	47-3478854
Entity Address, Address Line One	3259 Progress Drive
Entity Address, Address Line Two	Suite 114
Entity Address, City or Town	Orlando
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32826
City Area Code	(407)
Local Phone Number	956-2250
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 160,709	$ 28,474
Other prepaid expenses and deposit	2,290	6,290
Total Current Assets	162,999	34,764
EQUIPMENT:
Equipment	98,592	119,592
Accumulated depreciation	(60,385)	(34,954)
Total Equipment, net	38,207	84,638
INVESTMENT:	115,542
OTHER ASSETS:
Website	36,122	36,122
Accumulated amortization	(35,000)	(23,000)
Total Other Assets, net	1,122	13,122
TOTAL ASSETS	317,870	132,524
CURRENT LIABILITIES:
Accounts payable	131,719	141,417
Accrued compensation	671,500	492,825
Accrued expenses	188,700	104,040
Notes payable - related party	195,000	367,500
Promissory notes		90,000
Total Current Liabilities	1,186,919	1,195,782
STOCKHOLDERS' DEFICIT:
Preferred stock, 5,000,000 shares authorized, $.0001 par value, No shares issued and outstanding
Common stock, 100,000,000 shares authorized, $.0001 par value, 25,721,971 and 21,857,218 shares issued and outstanding December 31, 2020 and 2019, respectively	2,572	2,186
Common stock liability, 289,697 and 128,909 shares, $.0001 par value at December 31, 2020 and 2019, respectively	100,925	254,564
Additional paid in capital	6,021,201	4,549,058
Accumulated deficit	(6,993,747)	(5,869,066)
Total Stockholders' Deficit	(869,049)	(1,063,258)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 317,870	$ 132,524

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	25,721,971	21,857,218
Common stock, shares outstanding	25,721,971	21,857,218
Common stock liability, shares	289,697	128,909
Common stock liability, par value (in Dollars per share)	$ 0.0001	$ 0.0001

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue
OPERATING EXPENSES
Research and Development	3,000	60,874
Compensation Expense	812,190	2,509,792
General and Administrative	287,737	752,018
Impairment loss		43,548
Total Operating Expenses	1,102,927	3,366,232
OTHER INCOME AND (EXPENSES)
Gain on forgiveness of PPP Loan	4,630
Investment loss	(25,331)
Interest Earned	6	7
Interest Expense	(1,059)	(19,748)
Total Other Income and (Expenses), net	(21,754)	(19,741)
Loss before income tax taxes	(1,124,681)	(3,385,973)
Income tax provision
NET LOSS	$ (1,124,681)	$ (3,385,973)
Loss per common share - basic and diluted (in Dollars per share)	$ (0.05)	$ (0.16)
Weighted average common shares outstanding - basic and diluted (in Shares)	23,372,299	21,535,656

Statements of Operations (Paren

Statements of Operations (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Loss per common share - basic and diluted	$ (0.05)	$ (0.16)
Weighted average common shares outstanding - basic and diluted	23,372,299	21,535,656

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS OPERATING ACTIVITIES:
Net loss	$ (1,124,681)	$ (3,385,973)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	37,431	37,702
Impairment loss		43,548
Stock compensation expense	434,180	1,070,369
Stock issued for services		1,732,177
Concellation of common stock		(312,500)
Investment loss	25,331
Gain on forgiveness of PPP Loan	(4,630)
Non-cash interest		16,221
Changes in operating assets and liabilities:
Other prepaid expenses and deposit	4,000	(460)
Accounts payable and accrued expenses	537,829	374,811
Net Cash Used in Operating Activities	(90,540)	(424,105)
INVESTING ACTIVITIES:
Investment	(40,000)
Website costs		(122)
Equipment acquisition	(4,000)	(50,000)
Net Cash Used in Investing Activities	(44,000)	(50,122)
FINANCING ACTIVITIES:
Proceeds from notes payable related party	130,200	352,500
Proceeds from promissory notes	(65,000)	75,000
Proceeds from SBA	4,630
Proceeds from private placement	194,845
Proceeds from exercise of stock options	2,100	39,485
Net Cash Provided by Financing Activities	266,775	466,985
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	132,235	(7,242)
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	28,474	35,716
CASH AND CASH EQUIVALENTS - END OF YEAR	160,709	28,474
Non-cash investing activities:
Cash paid for interest	1,059	3,527
Cash paid for income taxes
Non-cash financing activities:
Equipment acquisition included in accounts payable		25,000
Related party note payable converted into common stock	302,700
Promissory note converted into common stock	45,000
Stock issued for investment acquisition	170,000
Reduction of account payable and equipment	$ 25,000

Statement of Shareholders' Defi

Statement of Shareholders' Deficit - USD ($)	Common Stock	Common Stock to be Issued	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 2,101	$ 81,312	$ 2,176,643	$ (2,483,093)	$ (223,037)
Balance (in Shares) at Dec. 31, 2018	21,007,446	65,050
Stock based compensation expense			1,070,369		1,070,369
Stock warrants			16,221		16,221
Stock issued for services	$ 89		1,507,597		1,507,686
Stock issued for services (in Shares)	889,772
Exercise of stock options	$ 21		39,464		39,485
Exercise of stock options (in Shares)	210,000
Common stock issuable for services		$ 173,252	51,239		224,491
Common stock issuable for services (in Shares)		63,859
Cancellation of stock	$ (25)		(312,475)		(312,500)
Cancellation of stock (in Shares)	(250,000)
Net loss				(3,385,973)	(3,385,973)
Balance at Dec. 31, 2019	$ 2,186	$ 254,564	4,549,058	(5,869,066)	(1,063,258)
Balance (in Shares) at Dec. 31, 2019	21,857,218	128,909
Stock based compensation expense			412,789		412,789
Stock warrants			29,921		29,921
Conversion of debt to equity	$ 181		302,519		302,700
Conversion of debt to equity (in Shares)	1,810,800
Stock issued for services	$ 44		195,045		195,089
Stock issued for services (in Shares)	436,023
Exercise of stock options	$ 2		2,098		2,100
Exercise of stock options (in Shares)	21,000
Private Placement	$ 112		194,730		194,842
Private Placement (in Shares)	1,124,708
Purchase of Investment	$ 47		169,953		170,000
Purchase of Investment (in Shares)	472,222
Common stock issuable for services		$ (153,639)	165,088		11,449
Common stock issuable for services (in Shares)		160,788
Net loss				(1,124,681)	(1,124,681)
Balance at Dec. 31, 2020	$ 2,572	$ 100,925	$ 6,021,201	$ (6,993,747)	$ (869,049)
Balance (in Shares) at Dec. 31, 2020	25,721,971	289,697

Financial Statements

Financial Statements	12 Months Ended
	Dec. 31, 2020
Financial Statements [Abstract]
FINANCIAL STATEMENTS	NOTE 1 – FINANCIAL STATEMENTS Organization AVRA Medical Robotics, Inc. (the “Company” or “AVRA”) was incorporated as AVRA Surgical Microsystems, Inc. in the State of Florida on February 4, 2015. Effective November 5, 2015, the Company’s corporate name was changed to AVRA Medical Robotics, Inc. The Company was established to develop advanced medical surgical devices. The Company is structured to invest in four principal areas – surgical robotic systems, surgical tools, implantable devices and surgical robotic training. Basis of Presentation The accompanying financial statements are prepared on the basis of accounting principles generally accepted in the United States of America (“GAAP”). The Company is a development-stage enterprise devoting substantial efforts to establishing a new business, financial planning, raising capital, and research into products which may become part of the Company’s product portfolio. The Company has not realized sales through December 31, 2020. A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and, even if planned principal operations have commenced, revenues are insignificant. Going Concern The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. At December 31, 2020, the Company’s stockholders’ deficit was $869,049 which raises substantial doubt about the Company. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect. While management of the Company believes that it will be successful in its capital formation and planned operating activities, there can be no assurance that the Company will be able to raise additional equity capital, or be successful in the development and commercialization of the products it develops or initiates collaboration agreements thereon. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management. Cash and Cash Equivalents The Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2020 and 2019, $0 were in excess of the FDIC insured limit. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition guidance in U.S. GAAP. The ASU also required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted the new standard effective January 1, 2018, the first day of the Company’s fiscal year. For these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial statements Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. The revenue recognition policies as enumerated below reflect the Company's accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition. Equipment Equipment is recorded at cost and depreciated using the straight-line method at rates determined to estimate the useful lives of the assets. The annual rates used in calculating depreciation are as follows: Equipment -5 years straight-line The Company originally purchased medical equipment for a total cost of $75,000 which was 100% financed by the seller. After making several payments, the Company settled with the vendor due to issues with equipment, and was relieved of the $25,000 balance owed as of first quarter 2020. The total amount paid of $50,000 represents the actual cost. Intangibles Intangible assets continue to be subject to amortization, and any impairment is determined in accordance with ASC 360, “Property, Plant, and Equipment,” intangible assets are stated at historical cost and amortized over their estimated useful lives. The Company uses a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined The Company purchased existing Intellectual Property from the University of Central Florida. Management regularly assesses the carrying value of the intellectual property to determine if there has been any diminution of value. Website Website is recorded at cost and amortized using the straight-line method over its estimated life of 3 years. Long-lived Assets In accordance with ASC 360, “ Property Plant and Equipment Stock Compensation Expense The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Accounting Standards Codification ("ASC") Topic 505, "Equity." Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC Topic 505. Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740 " Income Taxes. The Company applies the provisions of ASC Topic 740-10-05 " Accounting for Uncertainty in Income Taxes Basic and Diluted Loss per Share In accordance with ASC Topic 260 " Earnings Per Share, Research and Development Costs In accordance with ASC Topic 730 "Research and Development", with the exception of intellectual property that is purchased from another enterprise and have alternative future use, research and development expenses are charged to operations as incurred. Fair Value of Financial Instruments Our financial instruments consist principally of accounts receivable, amounts due to related parties and promissory notes payable. The carrying amounts of cash and cash equivalents and promissory notes approximate fair value because of the short-term nature of these items. Recent Accounting Pronouncements Compensation- Stock Compensation In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” that provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new guidance became effective for the Company on January 1, 2018 and was applied on a prospective basis, as required. The adoption of this standard did not have an impact on the financial statements or the related disclosures. Leases In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The FASB issued ASU 2016-02 to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under ASU 2016-02, lessors will account for leases using an approach that is substantially equivalent to existing GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective transition. The Company did not adopt the standard effective January 1, 2019, utilizing the lessor practical expedient. On November 15, 2019, the FASB issued ASU 2019-10 which amended the effective dates for ASC 842, to give implementation relief. Under the FASB's new framework, two "buckets" were defined, bucket 1 includes public companies that are SEC filers but excludes "Small Reporting Companies" (SRC's). Bucket 2 includes all other entities, including SRC's. Bucket 2 entities have to apply ASC 842 for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.

Investment

Investment	12 Months Ended
	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT	NOTE 3 – INVESTMENT On November 6, 2020, AVRA made an investment (the “Investment”) of $210,000 in Avra Air, LLC which was made with $40,000 in cash and the balance by the issuance to Avra Air, LLC of 472,222 restricted common shares of AVRA valued at $0.36 per Share. In exchange for the Investment AVRA received (a) a 49.8% limited liability company membership interest in Avra Air, LLC; and (b) the remaining 50% of a vehicular air sterilization provisional patent that AVRA did not yet control. In addition, AVRA agreed to pay Avra Air, LLC a royalty payment of $1.50 per vehicular air sterilization kit for two years from the date that a first kit that uses the patent is sold. On December 22, 2020, the Company issued 472,222 shares of its common stock towards its acquisition of Avra Air. LLC.

Notes Payable _ Related Party

Notes Payable – Related Party	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
NOTES PAYABLE – RELATED PARTY	NOTE 4 – NOTES PAYABLE – RELATED PARTY On December 31, 2018, the Company borrowed $15,000 under a non-interest bearing promissory note from a related party. The note matured on December 31, 2019 and was extended to December 31, 2020. On February 6, 2019, the Company borrowed from its CEO, $17,500 under a non interest bearing promissory note which matures on February 6, 2020 and was extended to December 31, 2020. On June 26, 2019, the Company borrowed from its CEO, $40,000 under a non interest bearing promissory note which matures on June 26, 2020 and was extended to December 31, 2020. On October 11, 2019, the Company borrowed from its CEO, $30,000 under a non interest bearing promissory note which matures on March 11, 2020 and was extended to December 31, 2020. On November 14, 2019, the Company borrowed from its CEO, $7,000 under a non interest bearing promissory note which matures on November 14, 2020 and was extended to December 31, 2020. On December 3, 2019, the Company borrowed from its CEO, $3,000 under a non interest bearing promissory note which matures on December 3, 2020. On December 6, 2019, the Company borrowed from its CEO, $30,000 under a non interest bearing promissory note which matures on December 6, 2020. On December 30, 2019, the Company borrowed from its CEO, $25,000 under a non interest bearing promissory note which matures on December 30, 2020. On March 31, 2020, the Company borrowed from its CEO, $6,000 under a non interest bearing promissory note which matures on December 31, 2020. On August 21, 2020, the Company borrowed from its CEO, $17,700 under a non interest bearing promissory note which matures on December 31, 2020 (see below). On October 19, 2020, the Company borrowed from its CEO, $11,500 under a non interest bearing promissory note which matures on December 31, 2021. On December 22, 2020, these notes totaling $202,700, totaling 202,700 units were all converted into 810,800 shares of common shares and a warrant was issued for 1,013,500 shares with an exercise price of $0.40/share. On May 4, 2020, the Company borrowed from its CEO, $2,500. On June 1, 2020, the Company borrowed from its CEO, $4,000. On June 30, 2020, the Company borrowed from its CEO, $5,000. On July 15, 2020, the Company borrowed from its CEO, $2,000. On July 20, 2020, the Company borrowed from its CEO, $1,000. On August 7, 2020, the Company borrowed from its CEO, $1,200. On August 21, 2020, the Company borrowed from its CEO, $2,000. On August 21, 2020, the Company entered into a non interest bearing promissory note with the total above combined funds of $17,700 which matures on December 31, 2020. This note was then part of the December 22, 2020 conversion (see above). On May 8, 2019, the Company borrowed from its CEO, $25,000 under a non interest bearing promissory note which matures on May 8, 2020 . On May 29, 2019, the Company borrowed from its CEO, $25,000 under a non interest bearing promissory note which matures on May 29, 2020 ... On July 19, 2019, the Company borrowed from its CEO, $50,000 under a non interest bearing promissory note which matures on July 19, 2020 . On August 26, 2019, the Company borrowed from its CEO, $100,000 under a non interest bearing promissory note which matured on December 26, 2019. On January 5, 2020, the related party used his $100,000 note to exercise his 1,000,000 options to purchase 1,000,000 shares of the Company’s common stock at $0.10 per share. During the year ended December 31, 2020 the Company received a Payroll Protection Loan (PPP Loan) in the amount of $4,630. Prior to December 31, 2020 the Company received forgiveness on the loan.

Promissory Notes

Promissory Notes	12 Months Ended
	Dec. 31, 2020
Promissory Notes [Abstract]
PROMISSORY NOTES	NOTE 5 – PROMISSORY NOTES On December 31, 2018, the Company borrowed $15,000, with interest payable annually at 4%, maturing on December 31, 2019. This note was paid in full on January 7, 2020. During January 2019, the Company borrowed $20,000 under a non interest bearing promissory note which matures on December 31, 2019, this amount was converted to 13,334 shares of common stock in 2020. On March 11, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 11, 2019. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. This note was paid in full on January 16, 2020. On March 14, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 14, 2019 and was extended until December 31, 2020. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. This note was paid in full on October 31, 2020. On March 29, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 29, 2019. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. This note was paid in full on January 21, 2020. During the years ended 2019 and 2020, 37,500 and 2,643,635 warrants, were valued at $51,740 and $471,825 using a black-scholes pricing model and expensed as stock compensation, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 6 – INCOME TAXES The Company’s deferred tax assets at December 31, 2020 consist of net operating loss carry forwards of $4,259,040. Using a new federal statutory tax rate of 21%, the valuation allowance balance as of December 31, 2019 total of $894,398. The increase in the valuation allowance balance for the year ended , 2020 Due to the uncertainty of their realization, no income tax benefits have been recorded by the Company for these loss carry forwards as valuation allowances have been established for any such benefits. The increase in the valuation allowance was the result of increases in the net operating losses discussed above. Therefore, the Company’s provision for income taxes is $-0- for the years ended , 2020 and 2019. At December 31, 2020 and 2019, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. At the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions. The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2020
Stockholders' Deficit [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 7 – STOCKHOLDERS’ DEFICIT The Company is authorized to issue up to 100,000,000 shares of common stock, $0.0001 par value per share plus 5,000,000 shares of preferred stock, par value $0.0001. On February 23, 2018, the board of directors of AVRA authorized the issuance of an aggregate of 218,000 shares of AVRA’s common stock (the “Shares”) as follows: ● 150,000 Shares at a value of $1.25 per Share, to six consultants and service providers for services rendered through December 31, 2017; ● 35,000 Shares, at a value of $1.25 per Share, to Farhan Taghizadeh, M.D., AVRA’s Chief Medical Officer, for services rendered during the period September 1, 2017 to December 31, 2017; and ● 19,500 and 13,500 Shares, at a value of $2.00 per Share, to Barry F. Cohen and A. Christian Schauer, our Chief Executive Officer and its former Chief Financial Officer, respectively, pursuant to Conversion Agreements with each of such officers, under which they converted all December 31, 2017 accrued but unpaid compensation due them under their respective employment agreements with the Company into the Shares. On August 13, 2018 the Company sold 16,000 shares of its common stock for $20,000. On October 4, 2018, the Board of Directors adopted the following resolutions and took the following actions by unanimous written consent in lieu of a meeting in accordance with the applicable provisions of the Florida business Corporation Act: ● 128,300 shares of restricted common stock required to be issued, to six consultants and service providers for services rendered through September 30, 2018; ● 400 shares of restricted common stock required to be issued, for services rendered through February 28, 2018; On January 4, 2019, 115,050 shares at a value of $1.25 per share were issued for service rendered. On April 1, 2019, 95,050 shares at a value ranging from $1.25-$2.41 per share were issued for services rendered. On July 1, 2019, 79,672 shares at a value ranging from $1.25-$2.76 per share were issued for services rendered. On August 28, 2019, 600,000 shares at a value ranging from $1.25-$2.00 per share were issued for services rendered. On December 1, 2019, the Company canceled 250,000 restricted shares of the Company’s common stock that were previously issued to its CEO under a Stock Award letter dated August 28, 2019. On November 6, 2020, AVRA issued an aggregate 256,027 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share; and (c) a 0.00008749_% limited liability company membership interest in Avra Air, LLC (“Avra Air”), a development stage company, which interest may be put to the Company at the option of the investor for a period of two years from issuance, in exchange for one Share. As a result of the foregoing, the investors were issued an aggregate of 1,024,108 Shares, warrants to purchase 1,280,135 Shares and a 22.4% limited liability company membership interest in Avra Air, LLC. On October 26, 2020, the Company received a commitment to sell 135,000 units for $135,000. A $25,000 promissory note plus accrued interest of $1,027 was converted towards the commitment for 26,027 units (this amount is included above). On November 6, 2020, AVRA issued an aggregate of 321,489 Shares as follows: ● 10,000 Shares to its Director Arthur Tomassetti per his prior advisory agreement; and ● 220,489 Shares to seven consultants, advisors, and service providers for services rendered through November 1, 2020; and ● 70,000 Shares to Farhan Taghizadeh, M.D., AVRA’s Chief Medical Officer, for services thru November 1, 2020; and ● 21,000 Shares for a stock option exercised by an investor at an exercise price of $0.10 per Share. During 2020, the Company’s CEO converted $302,700 of its notes payable into 1,810,800 shares of common stock. On December 22, 2020, the Company issued 472,222 shares of its common stock towards its acquisition of Avra Air (See Note 3). Holders are entitled to one vote for each share of common stock. No preferred stock has been issued.

2016 Incentive Stock Plan

2016 Incentive Stock Plan	12 Months Ended
	Dec. 31, 2020
2016 Incentive Stock Plan [Abstract]
2016 INCENTIVE STOCK PLAN	NOTE 8 – 2016 INCENTIVE STOCK PLAN On August 1, 2016, the Company adopted the 2016 Incentive Stock Plan (the “Plan”). The Plan provides for the granting of options to employees, directors, consultants and advisors to purchase up to 3,000,000 shares of the Company’s common stock. The Board is responsible for administration of the Plan. The Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair market value per common share on the date of the grant. On August 1, 2019, the Board increased the plan to 10,000,000 shares of common stock. For options granted October 1, 2017, the following factors were used: volatility 45.07%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted July 1, 2018, the following factors were used: volatility 31.34%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted May 1, 2018, the following factors were used: volatility 62.16%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. On July 1, 2018 options for 75,000 shares were issued to our Counsel for services rendered totaling $21,000. These shares are vested immediately and expire on July 1, 2023. The exercise price is $1.25. For the year ended December 31, 2019 and 2018, 210,000 and -0- options were exercised, respectively. Non-vested Options for 97,639 shares were forfeited during March 2018. On December 1, 2019, the Company granted to its majority shareholder options to purchase 750,000 common shares of the Company at an exercise price per share will be $1.00. All shares will immediately vest, and the Option will expire five years from the date of issuance. At December 31, 2020 and 2019 options representing 4,327,167 shares and 3,276,667 shares were vested or exercisable, respectively. All options issued to-date expire after five years from the issue date. Except for the option for 1,779,000 shares issued to the CEO and to the Company’s counsel for 40,000 shares that vested immediately, all the options issued to date vest over three years. Stock options are accounted for in accordance with FASB ASC Topic 718, Compensation –Stock Compensation The grant date fair value of options granted during the year of 2018 were estimated on the grant date using the Black-Scholes model with the following assumptions: For options granted May 1, 2018, the following factors were used; volatility 62.16%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted July 1, 2018, the following factors were used; volatility 31.34%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. The grant date fair value of options granted during the year of 2019 were estimated on the grant date using the Black-Scholes model with the following assumptions: For options granted February 1, 2019: Volatility 50.58%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted April 1, 2019: Volatility 48.52%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted August 1, 2019: Volatility 62.43%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted October 1, 2019: Volatility 48.57%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted December 1, 2019: Volatility 61.91%, term 3yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.00 per share. For the warrants granted on October 26, 2020 the fair market value used was $0.40, exercise $0.40, rate 2%, and volatility 44.35%. The warrants granted on December 22, 2020: Fair market value used was $0.468, exercise $0.40, rate 2%, and volatility 71.79%. For the options granted on December 22 2020 the fair market value used was $0.468, exercise $0.25, rate 2%, and volatility 71.79%. For the warrants granted on January 26 2021 the fair market value used was $0.980, exercise $0.40, rate 2%, and volatility 106.16%. Expected volatilities are based on the average volatilities of six similar companies; fair market values are calculated using the implied share values of recent company financings or OTC closing prices for that day, whichever is more suitable; risk-free rate used was 2%.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS	NOTE 9 – COMMITMENTS Intellectual property The Company purchased existing Intellectual Property from the University of Central Florida. Management regularly assesses the carrying value of the intellectual property to determine if there has been any diminution of value. Effective May 1, 2016, the Company entered into a Research Agreement (the “Research Agreement”) with the University of Central Florida (“UCF” or the “University”) for the development of a prototype surgical robotic device supporting minimal invasive surgical facial corrections. The Agreement provides that the University will provide personnel to accomplish the objectives as stated in the Statement of Work over a period extending to September 30, 2017. Effective May 1, 2016, the research agreement with the University of Central Florida has been extended to April 30, 2021. The Company agreed to extend funding of $163,307 from AVRA’s existing funds. The Company paid $43,548 for outright ownership of the University’s Intellectual Property resulting from the collaboration, which amount is shown as Intellectual Property. Management has assessed the carrying value of the asset at December 31, 2019 and has recorded an impairment loss in the amount of $43,548 for the year ended December 31, 2019. For the years ended, December 31 , 2020 and 2019, $-0- had been paid under the Agreement. The balance of the amount owing to the University was fully paid on February 24, 2017 and April 7, 2017. Additionally, a $68,952 matching funds grant from the Florida High Tech Corridor Council (FHTCC) was approved on July 16, 2016 which would provide the University research funds in addition to the Company’s funding obligation to the University. The FHTCC research grant is subject to certain research obligations and action requirements which if not met may result in the loss of the FHTCC research funding. The agreement further provides for the payment of a 1% royalty to the University in any year when the sales of products using the intellectual property exceeds $20,000,000. Employment Agreements On July 1, 2016, the Company entered into an Employment Agreement with its Chairman and Chief Executive Officer. The agreement provides for an annual salary of $120,000 per year, increasing to $180,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, and becoming fully vested on August 15, 2016. On August 1, 2016, the Company entered into a one-year Employment Agreement with its Chief Financial Officer. The agreement provides for an annual salary of $108,000 per year. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary. The options are to be surrendered and cancelled if the Agreement is terminated. The Agreement has expired but its compensation terms continue in effect as long as the employee remains employed by the Company. On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Business Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary. Further, on July 1, 2016, the Company entered into Indemnification Agreements with the Chairman and Chief Executive Officer, and on August 1, 2016 the Chief Financial Officer and the Vice-President of Global Business Development providing for the Company to indemnify the individuals for all expenses, judgments, etc. incurred while serving in various capacities with the Company. Commencing March 1, 2018, the Company entered into an employment agreement with its new Chief Strategy Officer whereby compensation will be determined upon sufficient funding of the Company. The Company granted a 300,000 share stock award under its 2016 Incentive Stock Plan, which vests in five equal annual installments of 60,000 shares each. In addition, on May 1, 2018 options for 250,000 shares that vest monthly over 3 years were also issued to our Chief Strategy Officer. These options expire on May 1, 2023 and are exercisable at $1.25. Commencing January 1, 2019, the Company entered into a consulting agreement with an IR/PR Company whereby compensation will be $1,500 per month for six months. During third quarter 2019, these services stopped. On July 1, 2019, the Company issued 36,000 restricted common shares as part of the compensation. Effective July, 1, 2020, the Company entered into an employee agreement with its Chairman and Chief Executive Officer, for a term of 48 months. The employee’s base salary is $15,000 monthly, beginning with the July 2020 payment, which rate shall be inclusive of all claims by the employee for his services. However, employee agrees to accrue his salary from the July 1, 2020 through and including December 2020 and allows the Board of Directors to decide on whether to convert any or all accrued salary into Company restricted common shares. Beginning on the July 1, 2020, normal direct business expenses will be covered, including business class travel on flights over 5 hours. Employee will receive a $500 per month vehicle expense stipend to help mitigate the costs of the frequent travel required to visit the Orlando office and University of Central Florida from the employee’s home. Employee will also be granted an option pursuant to the Company’s Equity Incentive Plan to purchase 1,000,000 restricted shares of the Company’s common stock, with an exercise price of $0.25 per share, and a Start Date of July 1, 2020. All 1,000,000 shares were Lease The Company occupies office and laboratory space in Orlando, Florida under a lease agreement that expired on July 31, 2018. Effective August 1, 2018 and expiring July 31, 2019, the Company signed a new agreement, with monthly payments of $1,829.25 plus applicable sales tax. Effective August 1, 2019, the Company signed a year lease agreement, provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $2,454.75 plus applicable sales tax. Effective January 15, 2020, the Company amended its August 1, 2019 lease agreement reducing its monthly lease payment to $2,223 plus applicable sales tax. On April 30, 2020, the rent due under our lease agreement had been reduced by 50% for the months of April and May, 2020. On July 17, 2020, the Company signed a lease that was effective August 1, 2020 through July 31, 2021, which provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $1,474.17 plus applicable sales tax. Either party may cancel the agreement at any time with 30 days’ notice.

Other Matters

Other Matters	12 Months Ended
	Dec. 31, 2020
Other Matters [Abstract]
OTHER MATTERS	NOTE 10 – OTHER MATTERS On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2020. On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES act was enacted as a response to the COVID-19 outbreak discussed above and is meant to provide companies with economic relief. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carry back periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date that the financial statements were issued and determined that there were subsequent events requiring adjustments to or disclosure in the financial statements. On January 26, 2021, AVRA issued an aggregate 235,000 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); and (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share. As a result of the foregoing, the investors were issued an aggregate of 940,000 Shares, and warrants to purchase 1,175,000 Shares. One of the accredited investors, per his original commitment in the Offering dated October 26, 2020, subsequently invested an additional $45,000 on May 3, 2021 in this same Unit funding thus receiving an additional 180,000 Shares, a warrant to purchase 225,000 Shares and a put option for 45,000 Shares. On June 3, 2021, the Board of Directors ratified the following issuances of common stock: 1. The Company issued 33,000 shares of restricted common stock required to be issued for services through June 1, 2021 to Farhan Taghizadeh, per his employment agreement dated September 15, 2020. 2. The Company issued 10,000 shares of restricted common stock required to be issued to Ettore Tomassetti per his Stock Award dated April 15, 2019. 3. The Company issued 160,000 shares of restricted common stock required to be issued to Nikhil Shah per his Stock Grant Award dated April 15, 2019 and his Employment Agreement dated March 1, 2018. 4. The Company issued 5,600 shares of restricted common stock required to be issued for services through June 1, 2021 to Maria Carin Bruck, per her services agreement dated October 1, 2018. 5. The Company issued 3.889 shares of restricted common stock required to be issued for services through June 1, 2021 to Robert Santangelo, per his services agreement dated February 15, 2019. 6. The Company issued 19,445 shares of restricted common stock required to be issued for services through June 1, 2021 to Vipul Patel, per his services agreement dated September 1, 2019. 7. The Company issued 7,000 shares of restricted common stock required to be issued for services through June 1, 2021 to Henry Gewanter, per his services agreement dated February 10, 2020. 8. The Company issued 19,444 shares of restricted common stock required to be issued to Jared Stammel per his Stock Award dated September 1, 2020. 9. The Company issued 25,000 shares of restricted common stock required to be issued to Robert Chanson, per his services agreement dated February 20, 2021. In July, 2021 several holders of stock options elected to exercise their stock options resulting in the issuance of 629,375 shares of common stock. On September 22, 2021, the Company’s CEO, converted $50,000 of accrued salary into 384,615 shares of common stock. On October 1, 2021, the Company’s CEO, converted a total of $595,000 of accrued salary into 5,950,000 shares of common stock at a price of $0.10 per share and agreed to receive 450,000 shares of common stock for $45,000 of the remaining salary due for the three months ending December 31, 2021at a price of $0.10 per share. On October 1, 2021, a former employee now a consultant elected to convert a total of $251,500 of accrued consulting fees into 2,515,000 shares of common stock at a price of $0.10 per share, converted $161,500 of accrued salary into 1,615,000 shares of common stock at a price of $0.10 per share. and $4,500 of expenses into 45,000 shares of common stock at a price of $0.10 per share. On October 1, 2021 the Company issued a total of 1,500,000 of stock options to consultants with an exercise price of $0.25 per option. On October 1, 2021 the Company issued 50,000 stock options to each of its independent Directors with an exercise price of $0.25 per option. On October 1, 2021 the Company issued 350,000 stock options to its Chief Medical Officer with an exercise price of $0.25 per option. On October 1, 2021 the Company issued a total of 390,000 stock options to the Company’s CEO with an exercise price of $0.25 per option for the extension of loans. On October 1, 2021 the Company issued a total of 174,553 shares of common stock to several consultants. On October 1, 2021 the Company issued 25,000 shares of common stock to its Chief Medical Officer. Between October 5, 2021 and December 8, 2021 the Company sold a total of 2,229,231 shares of common stock at prices ranging between $0.13 and $0.52 per share. The Company received proceeds of $315,200. On July 1, 2022 the Company paid $5,000 and issued to a consultant an option for 2,520,000 common shares with an exercise price of $0.10 per share as a performance bonus and for foregoing all accrued and unpaid fees due for 2022 and for foregoing a portion of the fees due for the remaining five months of calendar year 2022. The option vested immediately. On July 1, 2022 the Company issued to its CEO an option for 5,400,000 common shares with an exercise price of $0.10 per share as a performance bonus and for foregoing all of his 2022 salary. The option vested immediately. On July 1, 2022 the Company issued to its Chief Medical Officer an option for 500,000 common shares with an exercise price of $0.10 per share as a performance bonus. The option vested immediately. On July 1, 2022 the Company issued to its Chief Strategy Advisor an option for 500,000 common shares with an exercise price of $0.10 per share as a performance bonus. The option vested immediately. On July 1, 2022 the Company issued 240,270 shares of common stock as payment in full for the accrued but unpaid fees due to its Counsel. On July 1, 2022 the Company issued 27,250 shares of common stock to its patent attorney but their fee agreement. On July 1, 2022 the Company issued 160,000 shares of common stock to its Chief Strategy Officer as required by his Stock Grant Award dated April 15, 2019 and his Employment Agreement dated March 1, 2018. On July 1, 2022 the Company issued 40,000 shares of common stock to its Chief Medical Officer as required by his employment agreement dated September 15, 2020 On July 1, 2022 the Company issued a total of 569,747 shares of common stock to several consultants. In July 2022, four investors exercised their put options obtained from the Offering dated October 26, 2020, transferred their Membership Units in Avra Air LLC back to AVRA and received 301,027 shares of the Company’s common stock in return. On July 25, 2022 the Directors and Shareholders holding a majority of the issued and outstanding common shares of the Company adopted, by joint written consent, a resolution to increase the Company's common stock reserved for issuance under the Company’s 2016 Incentive Stock Plan to 20,000,000. On August 5, 2022, AVRA entered into a non-binding letter of intent with Dr. Sudhir Srivastava (“ Dr. Sudhir Cardio Otto SSI SSI Parties Transaction SSI Intellectual Property If and when the transaction is consummated, the business of the SSI Parties, including the SSI Intellectual Property will be owned by AVRA. The shareholders of the SSI Parties will own 95% of the common stock of post-transaction AVRA and the current shareholders of AVRA will own 5% of the common stock of post-transaction AVRA. In addition, there will be changes in composition of the board of directors, implementation of corporate governance policies and changes in management, all with a view to listing the common stock of AVRA on the Nasdaq Stock Market, LLC or another National Securities Exchange. In addition, AVRA will change its name to “ SS Innovations, Inc. Consummation of the Transaction is subject to, among other matters, the negotiation and execution of definitive agreements and documentation, containing, in addition to the above terms, terms and conditions customary for agreements of this type and nature, including, without limitation, representations, warranties, and indemnities of the parties. Consummation of the Transaction is also subject to completion of a due diligence review by each party of the other, the results of which shall be satisfactory to the reviewing parties in their sole discretion. Given the foregoing, there can be no assurance given that the Company will be able to successfully complete the Transaction. In connection with executing the letter of intent, we advanced the SSI Parties, the amount of $900,000 (the “ Interim Financing Cardio Note We may make additional advances to the SSI Parties of up to an aggregate principal amount of $5,000,000 of Interim Financing, evidenced by additional Cardio Notes. These Cardio Notes will be substantially similar in form and substance to the first Cardio Note, provided however 2.000,000 In order to fund the Interim Financing, the Company offered and sold to a single accredited investor, a $1,000,000 one-year convertible promissory note (the “ Convertible Note provided however The Convertible Note was issued in a private transaction pursuant to the exemptions from registration under the Section 4(a)2 of the Securities Act of 1933, as amended (the “ Securities Act In August 2022 the Company sold 1,000,000 shares of common stock at a price of $0.25 per share receiving proceeds of $250,000.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Estimates	Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2020 and 2019, $0 were in excess of the FDIC insured limit.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition guidance in U.S. GAAP. The ASU also required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted the new standard effective January 1, 2018, the first day of the Company’s fiscal year. For these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial statements Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. The revenue recognition policies as enumerated below reflect the Company's accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition.
Equipment	Equipment Equipment is recorded at cost and depreciated using the straight-line method at rates determined to estimate the useful lives of the assets. The annual rates used in calculating depreciation are as follows: Equipment -5 years straight-line The Company originally purchased medical equipment for a total cost of $75,000 which was 100% financed by the seller. After making several payments, the Company settled with the vendor due to issues with equipment, and was relieved of the $25,000 balance owed as of first quarter 2020. The total amount paid of $50,000 represents the actual cost.
Intangibles	Intangibles Intangible assets continue to be subject to amortization, and any impairment is determined in accordance with ASC 360, “Property, Plant, and Equipment,” intangible assets are stated at historical cost and amortized over their estimated useful lives. The Company uses a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined The Company purchased existing Intellectual Property from the University of Central Florida. Management regularly assesses the carrying value of the intellectual property to determine if there has been any diminution of value.
Website	Website Website is recorded at cost and amortized using the straight-line method over its estimated life of 3 years.
Long-lived Assets	Long-lived Assets In accordance with ASC 360, “ Property Plant and Equipment
Stock Compensation Expense	Stock Compensation Expense The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Accounting Standards Codification ("ASC") Topic 505, "Equity." Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC Topic 505.
Income Taxes	Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740 " Income Taxes. The Company applies the provisions of ASC Topic 740-10-05 " Accounting for Uncertainty in Income Taxes
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share In accordance with ASC Topic 260 " Earnings Per Share,
Research and Development Costs	Research and Development Costs In accordance with ASC Topic 730 "Research and Development", with the exception of intellectual property that is purchased from another enterprise and have alternative future use, research and development expenses are charged to operations as incurred.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Our financial instruments consist principally of accounts receivable, amounts due to related parties and promissory notes payable. The carrying amounts of cash and cash equivalents and promissory notes approximate fair value because of the short-term nature of these items.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
Compensation- Stock Compensation	Compensation- Stock Compensation In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” that provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new guidance became effective for the Company on January 1, 2018 and was applied on a prospective basis, as required. The adoption of this standard did not have an impact on the financial statements or the related disclosures.
Leases	Leases In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The FASB issued ASU 2016-02 to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under ASU 2016-02, lessors will account for leases using an approach that is substantially equivalent to existing GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective transition. The Company did not adopt the standard effective January 1, 2019, utilizing the lessor practical expedient. On November 15, 2019, the FASB issued ASU 2019-10 which amended the effective dates for ASC 842, to give implementation relief. Under the FASB's new framework, two "buckets" were defined, bucket 1 includes public companies that are SEC filers but excludes "Small Reporting Companies" (SRC's). Bucket 2 includes all other entities, including SRC's. Bucket 2 entities have to apply ASC 842 for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.

Financial Statements (Details)

Financial Statements (Details)	12 Months Ended
	Dec. 31, 2020 USD ($)
Financial Statements [Abstract]
Stockholders’ deficit	$ 869,049

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
FDIC insured	$ 250,000
FDIC insured limit	$ 0	$ 0
Equipment useful life	5 years
Medical equipment	$75,000
Percentage financed by the seller	100%
Equipment description	After making several payments, the Company settled with the vendor due to issues with equipment, and was relieved of the $25,000 balance owed as of first quarter 2020. The total amount paid of $50,000 represents the actual cost.
Estimated life	3 years

Investment (Details)

Investment (Details) - USD ($)	Nov. 06, 2020	Dec. 22, 2020
Investment (Details) [Line Items]
Price per share	$ 1.5
Avra Air, LLC [Member]
Investment (Details) [Line Items]
Investment	$ 210,000
Cash	$ 40,000
Restricted common shares	472,222
Price per share	$ 0.36
Limited liability interest percentage	49.80%
Remaining percentage	50%
Shares issued		472,222

Notes Payable _ Related Party (

Notes Payable – Related Party (Details) - USD ($)				12 Months Ended
	Sep. 22, 2021	Dec. 22, 2020	Jan. 05, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 08, 2021	Oct. 05, 2021	Oct. 01, 2021	Oct. 19, 2020	Aug. 26, 2020	Aug. 21, 2020	Aug. 07, 2020	Jul. 20, 2020	Jul. 15, 2020	Jun. 30, 2020	Jun. 01, 2020	May 04, 2020	Mar. 31, 2020	Jan. 03, 2020	Dec. 30, 2019	Dec. 06, 2019	Dec. 03, 2019	Nov. 14, 2019	Oct. 11, 2019	Jul. 19, 2019	Jun. 26, 2019	May 29, 2019	May 08, 2019	Feb. 06, 2019	Dec. 31, 2018
Notes Payable – Related Party (Details) [Line Items]
Notes total		$ 202,700
Total units (in Shares)		202,700
Converted shares of common shares (in Shares)		810,800
Warrant issued shares (in Shares)		1,013,500
Exercise price per share (in Dollars per share)		$ 0.4		$ 0.25
Combined funds											$ 17,700
Issued an option for common shares (in Shares)				390,000
Related party			$ 100,000	$ 195,000	$ 367,500
Exercise options (in Dollars per share)			$ 1,000,000
Purchase shares (in Shares)			1,000,000
Common stock per share (in Dollars per share)			$ 0.1
Payroll protection loan amount				$ 4,630
Common Stock [Member]
Notes Payable – Related Party (Details) [Line Items]
Purchase shares (in Shares)					(250,000)
Forecast [Member]
Notes Payable – Related Party (Details) [Line Items]
Converted shares of common shares (in Shares)	384,615
Exercise price per share (in Dollars per share)								$ 0.1
Forecast [Member] | Common Stock [Member]
Notes Payable – Related Party (Details) [Line Items]
Converted shares of common shares (in Shares)	384,615
Exercise price per share (in Dollars per share)						$ 0.52	$ 0.13
Chief Executive Officer [Member]
Notes Payable – Related Party (Details) [Line Items]
Non-interest bearing promissory note									$ 11,500	$ 100,000	2,000	$ 1,200	$ 1,000	$ 2,000	$ 5,000	$ 4,000	$ 2,500		$ 95,000						$ 50,000		$ 25,000	$ 25,000
Promissory Note [Member]
Notes Payable – Related Party (Details) [Line Items]
Non-interest bearing promissory note																														$ 15,000
Promissory Note [Member] | Chief Executive Officer [Member]
Notes Payable – Related Party (Details) [Line Items]
Non-interest bearing promissory note											$ 17,700							$ 6,000		$ 25,000	$ 30,000	$ 3,000	$ 7,000	$ 30,000		$ 40,000			$ 17,500

Promissory Notes (Details)

Promissory Notes (Details) - USD ($)			1 Months Ended		12 Months Ended
	Mar. 14, 2019	Mar. 11, 2019	Mar. 29, 2019	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019
Promissory Notes (Details) [Line Items]
Maturity date	Sep. 14, 2019	Sep. 11, 2019	Sep. 29, 2019	Dec. 31, 2019		Dec. 31, 2019
Number of warrants purchase (in Shares)	12,500
Strike price (in Dollars per share)	$ 1.25
Warrant expiration period	3 years
Warrants (in Shares)					2,643,635		37,500
Warrants					$ 471,825		$ 51,740
Promissory Note [Member]
Promissory Notes (Details) [Line Items]
Borrowed amount	$ 25,000	$ 25,000	$ 25,000	$ 20,000		$ 15,000
Debt default interest rate	5%	5%	5%			4%
Common stock shares converted (in Shares)					13,334
Number of warrants purchase (in Shares)		12,500	12,500
Strike price (in Dollars per share)		$ 1.25	$ 1.25
Warrant expiration period		3 years	3 years

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 4,259,040
Federal statutory tax rate		21%
Federal tax benefit valuation allowance		$ 894,398
Net operating loss	221,827
Provision for income taxes	$ 0	$ 0

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($)

1 Months Ended

12 Months Ended

Oct. 01, 2021

Nov. 06, 2020

Oct. 26, 2020

Dec. 01, 2019

Aug. 13, 2018

Feb. 28, 2018

Sep. 30, 2018

Dec. 31, 2020

Jul. 01, 2022

Dec. 22, 2020

Nov. 01, 2020

Dec. 31, 2019

Aug. 28, 2019

Jul. 01, 2019

Apr. 01, 2019

Jan. 04, 2019

Feb. 23, 2018

Dec. 31, 2017

Stockholders' Deficit (Details) [Line Items]

Common stock, shares authorized

100,000,000

100,000,000

Common stock, par value (in Dollars per share)

$ 0.0001

$ 0.0001

Preferred stock, shares authorized

5,000,000

5,000,000

Preferred stock, par value (in Dollars per share)

$ 0.0001

$ 0.0001

Aggregate of shares

321,489

218,000

Shares value

600,000

79,672

95,050

115,050

Price per share (in Dollars per share)

$ 0.1

$ 2

Sold shares

16,000

Shares of ommon stock (in Dollars)

$ 20,000

Shares of restricted common stock required to be issued

400

Per share issued for service (in Dollars per share)

$ 1.25

Restricted shares

250,000

Description of AVRA issued an aggregate

On November 6, 2020, AVRA issued an aggregate 256,027 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share; and (c) a 0.00008749_% limited liability company membership interest in Avra Air, LLC (“Avra Air”), a development stage company, which interest may be put to the Company at the option of the investor for a period of two years from issuance, in exchange for one Share. As a result of the foregoing, the investors were issued an aggregate of 1,024,108 Shares, warrants to purchase 1,280,135 Shares and a 22.4% limited liability company membership interest in Avra Air, LLC.

Received a commitment to sell units

135,000

Commitment to sell units amount (in Dollars)

$ 135,000

Promissory note (in Dollars)

25,000

Accrued interest (in Dollars)

$ 1,027

Commitment units

26,027

Shares for a stock option exercised

21,000

Exercise price per share (in Dollars per share)

$ 0.1

Shares of common stock

45,000

1,810,800

Common stock shares issued

25,721,971

21,857,218

Common Stock [Member]

Stockholders' Deficit (Details) [Line Items]

Common stock shares issued

2,520,000

Common stock voting rights, description

Holders are entitled to one vote for each share of common stock.

Minimum [Member]

Stockholders' Deficit (Details) [Line Items]

Per share issued for service (in Dollars per share)

$ 1.25

$ 1.25

$ 1.25

Maximum [Member]

Stockholders' Deficit (Details) [Line Items]

Per share issued for service (in Dollars per share)

$ 2

$ 2.76

$ 2.41

Chief Executive Officer [Member]

Stockholders' Deficit (Details) [Line Items]

Converted of notes payable (in Dollars)

$ 302,700

Farhan Taghizadeh [Member]

Stockholders' Deficit (Details) [Line Items]

Shares value

35,000

Director Arthur Tomassetti [Member]

Stockholders' Deficit (Details) [Line Items]

Shares value

10,000

Seven Consultants, Advisors, and Service Providers [Member]

Stockholders' Deficit (Details) [Line Items]

Shares value

220,489

Farhan Taghizadeh, M.D., AVRA’s Chief Medical Officer [Member]

Stockholders' Deficit (Details) [Line Items]

Shares value

70,000

Avra Air [Member]

Stockholders' Deficit (Details) [Line Items]

Common stock shares issued

472,222

Six Consultants and Service Providers [Member]

Stockholders' Deficit (Details) [Line Items]

Shares value

150,000

Price per share (in Dollars per share)

$ 1.25

Shares of restricted common stock required to be issued

128,300

Farhan Taghizadeh [Member]

Stockholders' Deficit (Details) [Line Items]

Price per share (in Dollars per share)

$ 1.25

Barry F. Cohen [Member]

Stockholders' Deficit (Details) [Line Items]

Shares value

19,500

A. Christian Schauer [Member]

Stockholders' Deficit (Details) [Line Items]

Shares value

13,500

2016 Incentive Stock Plan (Deta

2016 Incentive Stock Plan (Details) - 2016 Incentive Stock Plan [Member] - USD ($)													12 Months Ended
	Jan. 26, 2021	Dec. 22, 2020	Oct. 26, 2020	Dec. 01, 2019	Oct. 01, 2019	Aug. 01, 2019	Apr. 01, 2019	Feb. 01, 2019	Jul. 01, 2018	May 01, 2018	Mar. 31, 2018	Oct. 01, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Aug. 01, 2016
2016 Incentive Stock Plan (Details) [Line Items]
Shares of common stock (in Shares)						10,000,000										3,000,000
Expected volatility	106.16%	71.79%	44.35%	61.91%	48.57%	62.43%	48.52%	50.58%	31.34%	62.16%		45.07%
Expected term									3 years	3 years		3 years
Risk-free interest rate	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%		2%	2%
Expected dividend yield				0%	0%	0%	0%	0%	0%	0%		0%
Exercise price per share (in Dollars per share)	$ 0.4	$ 0.25	$ 0.4	$ 1	$ 2	$ 2	$ 1.25	$ 2	$ 1.25	$ 1.25		$ 1.25
Shares issued (in Shares)									75,000
Share issued during the period, value (in Dollars)									$ 21,000
Option expiration date									Jul. 01, 2023
Option exercised (in Shares)														210,000	0
Shares forfeited (in Dollars per share)											$ 97,639
Shareholder options purchased (in Shares)				750,000
Exercise price (in Dollars per share)				$ 1
Option expire				5 years
Number of shares vested (in Shares)													4,327,167	3,276,667
Share options issued description													All options issued to-date expire after five years from the issue date. Except for the option for 1,779,000 shares issued to the CEO and to the Company’s counsel for 40,000 shares that vested immediately, all the options issued to date vest over three years.
Unrecognized compensation cost (in Dollars)													$ 204,038
Non-vested options recognized period													30 months
Expiring term													Jun. 30, 2023
Expected term				3yrs	3yrs	3yrs	3yrs	3yrs
Fair market value (in Dollars per share)			$ 0.4
Fair market value per share (in Dollars per share)	$ 0.98	$ 0.468
Warrant [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Expected volatility		0.468%
Risk-free interest rate		0.40%
Expected dividend yield		2%
Exercise price per share (in Dollars per share)		$ 0.7179
Options [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Expected volatility									31.34%	62.16%
Expected term									3 years	3 years
Risk-free interest rate									2%	2%
Expected dividend yield									0%	0%
Exercise price per share (in Dollars per share)									$ 1.25	$ 1.25
Counsel for Services [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Exercise price per share (in Dollars per share)									$ 1.25
General and Administrative Expense [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Stock based compensation (in Dollars)													$ 1,088,854

Commitments (Details)

Commitments (Details) - USD ($)									12 Months Ended
	Jul. 01, 2020	Jul. 01, 2019	Jan. 01, 2019	May 01, 2018	Mar. 01, 2018	Aug. 01, 2016	Jul. 16, 2016	Jul. 01, 2016	Dec. 31, 2020	Dec. 31, 2019
Commitments (Details) [Line Items]
Collateralized Agreements									$ 0	$ 0
Employment agreements description						On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Business Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary.
Expire date									May 01, 2023
Options exercisable (in Dollars per share)									$ 1.25
Restricted common shares (in Shares)	1,000,000
Employee agreement term		48 months
Employee’s base salary		$ 15,000
Vehicle expenses									$ 500
Exercise price (in Dollars per share)	$ 0.25
Lease description									The Company occupies office and laboratory space in Orlando, Florida under a lease agreement that expired on July 31, 2018. Effective August 1, 2018 and expiring July 31, 2019, the Company signed a new agreement, with monthly payments of $1,829.25 plus applicable sales tax. Effective August 1, 2019, the Company signed a year lease agreement, provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $2,454.75 plus applicable sales tax. Effective January 15, 2020, the Company amended its August 1, 2019 lease agreement reducing its monthly lease payment to $2,223 plus applicable sales tax. On April 30, 2020, the rent due under our lease agreement had been reduced by 50% for the months of April and May, 2020. On July 17, 2020, the Company signed a lease that was effective August 1, 2020 through July 31, 2021, which provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $1,474.17 plus applicable sales tax. Either party may cancel the agreement at any time with 30 days’ notice.
Intellectual Property [Member]
Commitments (Details) [Line Items]
Extend funding value									$ 163,307
Ownership amount									$ 43,548
Impairment loss amount										$ 43,548
Research funds value							$ 68,952
Royalty payment percentage									1%
Intellectual property exceeds									$ 20,000,000
Employment Agreements [Member]
Commitments (Details) [Line Items]
Shares stock award (in Shares)					300,000
Installments shares (in Shares)					60,000
Options shares vest (in Shares)				250,000
Vest date				3 years
Whereby compensation			$ 1,500
Restricted common shares (in Shares)		36,000
Chief Executive Officer [Member]
Commitments (Details) [Line Items]
Employment agreements description								On July 1, 2016, the Company entered into an Employment Agreement with its Chairman and Chief Executive Officer. The agreement provides for an annual salary of $120,000 per year, increasing to $180,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, and becoming fully vested on August 15, 2016.
Shares fully vested (in Shares)	1,000,000
Chief Financial Officer [Member]
Commitments (Details) [Line Items]
Employment agreements description						On August 1, 2016, the Company entered into a one-year Employment Agreement with its Chief Financial Officer. The agreement provides for an annual salary of $108,000 per year. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary. The options are to be surrendered and cancelled if the Agreement is terminated. The Agreement has expired but its compensation terms continue in effect as long as the employee remains employed by the Company.

Subsequent Events (Details)

Subsequent Events (Details)

1 Months Ended

12 Months Ended

Jul. 01, 2022 USD ($) $ / shares shares

Oct. 05, 2021 USD ($) $ / shares shares

Oct. 01, 2021 USD ($) $ / shares shares

Jan. 26, 2021 $ / shares shares

Nov. 06, 2020 $ / shares

Oct. 26, 2020

Aug. 31, 2022 USD ($) $ / shares shares

Jul. 31, 2022 shares

Sep. 22, 2021 USD ($) shares

Jan. 26, 2021 $ / shares shares

Dec. 31, 2020 USD ($) $ / shares shares

Dec. 31, 2019 USD ($) $ / shares shares

Jul. 25, 2022 shares

Dec. 08, 2021 $ / shares

Jul. 01, 2021 shares

Jun. 01, 2021 shares

Feb. 20, 2021 shares

Dec. 22, 2020 $ / shares

Sep. 01, 2020 shares

Apr. 15, 2019 shares

Jan. 04, 2019 $ / shares

Dec. 31, 2017 $ / shares

Subsequent Events (Details) [Line Items]

Price per share (in Dollars per share) | $ / shares

$ 0.1

Purchase of warrants

2,643,635

37,500

Private offering description

October 26, 2020, subsequently invested an additional $45,000 on May 3, 2021 in this same Unit funding thus receiving an additional 180,000 Shares, a warrant to purchase 225,000 Shares and a put option for 45,000 Shares.

Shares issued

25,721,971

21,857,218

Price per share (in Dollars per share) | $ / shares

$ 0.0001

$ 0.0001

Accrued salary (in Dollars) | $

$ 671,500

$ 492,825

Price per share (in Dollars per share) | $ / shares

$ 0.25

$ 0.4

Shares of common stock

45,000

1,810,800

Common stock at a price per share (in Dollars per share) | $ / shares

$ 0.1

$ 2

Gross proceeds (in Dollars) | $

$ 315,200

$ 195,089

1,507,686

Price per share (in Dollars per share) | $ / shares

$ 1.25

Principal amount (in Dollars) | $

$ 2

issued discount

10%

Conversion amount (in Dollars) | $

$ 100,000,000

Convertible note ,description

the Company offered and sold to a single accredited investor, a $1,000,000 one-year convertible promissory note (the “Convertible Note”). The Convertible Note will have the same interest rate and payment terms as the Cardio Note and otherwise be substantially similar to the Cardio Note, provided, however, that the Convertible Note does not have an original issue discount. Further, upon consummation of the Transaction (if and when it is consummated) the Convertible Note will automatically convert into a number of AVRA Shares determined by dividing the principal amount of the Convertible Note by $100 million and multiplying such number expressed as a percentage by the number of AVRA Shares issued to Dr. Sudhir and the other shareholders of the SSI Parties (if any) upon closing of the Transaction. The Company may offer and sell up to an aggregate principal amount of $5,000,000 in Convertible Notes in order to fund the Interim Financing.

Common Stock [Member]

Subsequent Events (Details) [Line Items]

Shares issued

2,520,000

Gross proceeds (in Dollars) | $

$ 44

$ 89

SSI Parties [Member]

Subsequent Events (Details) [Line Items]

Shareholders percentage

95%

Subsequent Event [Member] | Private Placement [Member]

Subsequent Events (Details) [Line Items]

Aggregate units

235,000

Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

1,000,000

629,375

Employee agreement description

On October 1, 2021, the Company’s CEO, converted a total of $595,000 of accrued salary into 5,950,000 shares of common stock at a price of $0.10 per share and agreed to receive 450,000 shares of common stock for $45,000 of the remaining salary due for the three months ending December 31, 2021at a price of $0.10 per share.

Price per share (in Dollars per share) | $ / shares

$ 0.25

Accrued salary (in Dollars) | $

$ 161,500

Shares issued

1,615,000

Price per share (in Dollars per share) | $ / shares

$ 0.1

Expenses (in Dollars) | $

$ 4,500

Stock options issued

1,500,000

Exercise price (in Dollars per share) | $ / shares

$ 0.25

Gross proceeds (in Dollars) | $

$ 250,000

Paid amount (in Dollars) | $

$ 5,000

Number of investors

4

Forecast [Member] | Warrant [Member]

Subsequent Events (Details) [Line Items]

Purchase of warrants

1,175,000

1,175,000

Forecast [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Shares issued

2,229,231

174,553

Price per share (in Dollars per share) | $ / shares

$ 0.13

$ 0.52

Price per share (in Dollars per share) | $ / shares

$ 0.1

Forecast [Member] | Private Placement [Member]

Subsequent Events (Details) [Line Items]

Aggregate units per share (in Dollars per share) | $ / shares

$ 1

Description Of warrants shares

Each Unit consisted of (a) four shares of our common stock (“Shares”); and (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share.

Forecast [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Price per share (in Dollars per share) | $ / shares

$ 0.4

2016 Incentive Stock Plan [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

20,000,000

Director [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Stock options issued

50,000

Exercise price (in Dollars per share) | $ / shares

$ 0.25

AVRA Medical Robotics Inc [Member] | SSI Parties [Member]

Subsequent Events (Details) [Line Items]

Shareholders percentage

5%

Investor [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Aggregate units

940,000

Farhan Taghizadeh [Member] | Board of Directors Chairman [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

33,000

Ettore Tomassetti [Member]

Subsequent Events (Details) [Line Items]

Stock award date

April 15, 2019

Ettore Tomassetti [Member] | Board of Directors Chairman [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

10,000

Nikhil Shah [Member]

Subsequent Events (Details) [Line Items]

Stock award date

April 15, 2019

Nikhil Shah [Member] | Board of Directors Chairman [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

160,000

Maria Carin Bruck [Member] | Board of Directors Chairman [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

5,600

Robert Santangelo [Member] | Board of Directors Chairman [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

3.889

Vipul Patel [Member] | Board of Directors Chairman [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

19,445

Services agreement date

September 1, 2019

Henry Gewanter [Member] | Board of Directors Chairman [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

7,000

Jared Stammel [Member] | Board of Directors Chairman [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

19,444

Stock award date

September 1, 2020

Robert Chanson [Member] | Board of Directors Chairman [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

25,000

Services agreement date

February 20, 2021

CEO [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

5,400,000

Converted notes (in Dollars) | $

$ 50,000

Conversion of common stock shares

384,615

Price per share (in Dollars per share) | $ / shares

$ 0.1

Stock options issued

390,000

Exercise price (in Dollars per share) | $ / shares

$ 0.25

Six consultants [Member]

Subsequent Events (Details) [Line Items]

Common stock at a price per share (in Dollars per share) | $ / shares

1.25

Six consultants [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Accrued consulting fees (in Dollars) | $

$ 251,500

Six consultants [Member] | Forecast [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Shares issued

2,515,000

Price per share (in Dollars per share) | $ / shares

$ 0.1

Chief Medical Officer [Member]

Subsequent Events (Details) [Line Items]

Common stock at a price per share (in Dollars per share) | $ / shares

$ 1.25

Chief Medical Officer [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

25,000

Stock options issued

350,000

Exercise price (in Dollars per share) | $ / shares

$ 0.25

Chief Medical Officer [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

500,000

Price per share (in Dollars per share) | $ / shares

$ 0.1

Chief Medical Officer [Member] | Forecast [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

40,000

Chief Strategy Officer [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

500,000

Price per share (in Dollars per share) | $ / shares

$ 0.1

Chief Strategy Officer [Member] | Forecast [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

160,000

Stock award date

April 15, 2019

Consultant [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

240,270

Consultant [Member] | Forecast [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Shares issued

569,747

Attorney [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

27,250

Avra Air LLC [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

301,027

SSI Parties [Member]

Subsequent Events (Details) [Line Items]

Converted notes (in Dollars) | $

$ 1,000,000

Paid amount (in Dollars) | $

$ 900,000

Interest rate

7%

Discount rate percentage

10%

Accrued interest (in Dollars) | $

$ 100,000,000

Principal amount (in Dollars) | $

$ 5,000,000

issued discount

6%

Conversion amount (in Dollars) | $

$ 250,000,000